K36 Therapeutics, Inc.
Clinical trials sponsored by K36 Therapeutics, Inc., explained in plain language.
-
New pill takes aim at Hard-to-Treat blood cancer
Disease control Recruiting nowThis early-stage trial tests an experimental pill called KTX-1001 in adults with multiple myeloma that has returned or not responded to at least three prior treatments. The study aims to find a safe dose and see if the drug can shrink tumors or slow the cancer. About 125 particip…
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 02, 2026 21:17 UTC
-
New drug combo targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX2001, alone or with another drug (darolutamide), in men with advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check safety, find the best dose, and see how the drug works in the b…
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC